Reviva Pharmaceuticals aims to improve schizophrenia treatment with Brilaroxazine. Learn why RVPH stock offers potential ...

A new analysis summarizes a decade of research on the effects of a psychedelic brew on anxiety and trauma responses. With the ...

Recent research found that Psilocybe cubensis extract improved memory and increased brain plasticity-related protein levels ...

Their team is developing New Chemical Entities (NCEs) that act on the serotonin receptor as therapies for treatment-resistant mental health conditions. In targeting compounds that act on the 5-HT2A ...

New research explores how ayahuasca influences brain circuits involved in fear and anxiety, offering insights into its potential therapeutic uses ...

Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster presentations showcasing the potential of bexicaserin in Developmental and Epileptic ...

The drug has shown strong results in phase 3 clinical trials, which are the basis for the new application to the FDA.

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

The review synthesizes evidence showing that ayahuasca's effects involve a delicate balance between two serotonin receptor types: 5-HT2A and 5-HT1A. This dual action appears crucial for understanding ...

As interest in psychedelic medicine grows, researchers have synthesized a decade of evidence to understand how ayahuasca ...

A comprehensive review published in Psychedelics examines the current understanding of how ayahuasca, a traditional Amazonian ...

SF is a 50-year-old woman, counseled about the therapeutic use of psilocybin by her neurologist, who has participated in ...